Sorafenib tosylate in advanced kidney cancer: past, present and future
Camillo Porta(University of Pavia), Elisa Ferraris(Fondazione Salvatore Maugeri), Chiara Paglino, Ilaria Imarisio(University of Pavia)
Cited by 23
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2012|275